ERBB2 and breast carcinoma: The need to relativize the traditional dichotomization between HER2-positive and HER2-negative appeared at the latest with the results of the DESTINY-Breast04 trial, which demonstrated the superiority of trastuzumab-deruxtecan (T-DXd) vs. chemotherapy of the physician’s choice in patients with advanced HER2-low breast cancer [37].